Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
ENDO PHARMACEUTICALS INC. v. IMPAX LABORATORIES, INC.
Case Number:
2:16-cv-02526
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
July 12, 2016
Impax Looks To Duck Endo's $100M Suit Over Drug Licensing
Generic-drug maker Impax Laboratories asked a New Jersey federal judge Monday to toss Endo Pharmaceuticals' $100 million lawsuit alleging it is refusing to negotiate royalty payments on a generic version of the painkiller Opana ER, saying a 2010 settlement allows royalty-free marketing and sale of the drug.
-
May 06, 2016
Endo Hits Impax With $100M Suit Over Painkiller IP Agreement
Endo Pharmaceuticals Inc. launched a suit in New Jersey federal court Wednesday claiming generic drugmaker Impax Laboratories owes it more than $100 million for breaching a patent licensing agreement by refusing to negotiate compensation payments for the marketing and sale of a generic version of painkiller Opana ER.